AU2019338459B2 - Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses therefor - Google Patents

Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses therefor Download PDF

Info

Publication number
AU2019338459B2
AU2019338459B2 AU2019338459A AU2019338459A AU2019338459B2 AU 2019338459 B2 AU2019338459 B2 AU 2019338459B2 AU 2019338459 A AU2019338459 A AU 2019338459A AU 2019338459 A AU2019338459 A AU 2019338459A AU 2019338459 B2 AU2019338459 B2 AU 2019338459B2
Authority
AU
Australia
Prior art keywords
administration
pai
hours
site
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019338459A
Other languages
English (en)
Other versions
AU2019338459A1 (en
Inventor
Jonathan Edelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eirion Therapeutics Inc
Original Assignee
Eirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirion Therapeutics Inc filed Critical Eirion Therapeutics Inc
Publication of AU2019338459A1 publication Critical patent/AU2019338459A1/en
Application granted granted Critical
Publication of AU2019338459B2 publication Critical patent/AU2019338459B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Biophysics (AREA)
AU2019338459A 2018-09-13 2019-09-12 Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses therefor Active AU2019338459B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731074P 2018-09-13 2018-09-13
US62/731,074 2018-09-13
PCT/US2019/050849 WO2020056160A1 (en) 2018-09-13 2019-09-12 Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Publications (2)

Publication Number Publication Date
AU2019338459A1 AU2019338459A1 (en) 2021-04-08
AU2019338459B2 true AU2019338459B2 (en) 2025-07-10

Family

ID=68052024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019338459A Active AU2019338459B2 (en) 2018-09-13 2019-09-12 Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses therefor

Country Status (14)

Country Link
US (1) US20220105068A1 (cg-RX-API-DMAC7.html)
EP (1) EP3849539B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021535925A (cg-RX-API-DMAC7.html)
KR (2) KR102884331B1 (cg-RX-API-DMAC7.html)
CN (2) CN113056268A (cg-RX-API-DMAC7.html)
AU (1) AU2019338459B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004542A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112558A1 (cg-RX-API-DMAC7.html)
DK (1) DK3849539T3 (cg-RX-API-DMAC7.html)
ES (1) ES3076115T3 (cg-RX-API-DMAC7.html)
IL (1) IL281450A (cg-RX-API-DMAC7.html)
MX (2) MX2021002995A (cg-RX-API-DMAC7.html)
SG (1) SG11202102478SA (cg-RX-API-DMAC7.html)
WO (1) WO2020056160A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN113155987B (zh) * 2020-12-28 2023-06-06 浙江工商大学 一种微针贴片及其制备方法、应用
IL327134A (en) 2023-09-18 2026-05-01 Eirion Therapeutics Inc Topical formulations and uses of PAI-1 inhibitors
WO2026090113A1 (en) * 2024-10-21 2026-04-30 Versiti Blood Research Institute Foundation, Inc. Modifying transplantable organs ex vivo with rna lipid nanoparticle perfusion
WO2026147911A1 (en) * 2024-12-30 2026-07-09 Eirion Therapeutics, Inc. Topical compositions and regimens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003071267A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
WO2001051085A1 (en) * 2000-01-14 2001-07-19 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
EP2377532A1 (en) * 2004-08-18 2011-10-19 Ace ApS Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists for treating dermatological disorders
PL3144013T3 (pl) 2005-12-01 2019-04-30 Univ Of Massachusetts Lowell Nanoemulsje botulinowe
EP2015773A4 (en) 2006-04-27 2010-05-05 Anterios Inc EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
WO2009123241A1 (ja) * 2008-03-31 2009-10-08 株式会社レナサイエンス プラスミノーゲンアクチベーターインヒビター－１阻害剤
MX2010013562A (es) 2008-06-26 2011-02-15 Anterios Inc Aplicacion dermica.
ES2621849T3 (es) * 2009-06-26 2017-07-05 Sunny Pharmtech Inc. Método de tratamiento o mejora de toxicidades mucocutáneas u oculares.
ES2720648T3 (es) 2011-01-24 2019-07-23 Anterios Inc Composiciones de nanopartículas
AU2012209274A1 (en) 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
US9144671B2 (en) 2011-12-21 2015-09-29 3M Innovative Properties Company Transdermal adhesive patch assembly with removable microneedle array and method of using same
WO2020056191A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003071267A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FARHATULLAH SYED ET AL: "Ex vivo evaluation of antifibrotic compounds in skin scarring: EGCG and silencing of PAI-1 independently inhibit growth and induce keloid shrinkage", LAB INVESTIGATION, vol. 93, no. 8, 8 July 2013, pages 946 - 960 *
G. RANIERI ET AL: "Defibrotide in the treatment of Raynaud's phenomenon in patients with progressive systemic sclerosis or essential mixed cryoglobulinemia", CURRENT THERAPEUTIC RESEARCH, vol. 53, no. 1, 1 January 1993, pages 48 - 58 *

Also Published As

Publication number Publication date
MX2021002995A (es) 2021-07-15
IL281450A (en) 2021-04-29
US20220105068A1 (en) 2022-04-07
EP3849539A1 (en) 2021-07-21
DK3849539T3 (da) 2026-07-27
ES3076115T3 (en) 2026-08-12
CN113056268A (zh) 2021-06-29
MX2025004193A (es) 2025-05-02
BR112021004542A2 (pt) 2021-06-08
WO2020056160A1 (en) 2020-03-19
KR20210057141A (ko) 2021-05-20
JP2021535925A (ja) 2021-12-23
JP2025011085A (ja) 2025-01-23
SG11202102478SA (en) 2021-04-29
AU2019338459A1 (en) 2021-04-08
CN120983628A (zh) 2025-11-21
KR102884331B1 (ko) 2025-11-13
KR20250163416A (ko) 2025-11-20
EP3849539B1 (en) 2026-07-01
CA3112558A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
AU2019339488B2 (en) Uses of plasminogen activator inhibitor 1 (PAI-1) inhibitors
KR102884331B1 (ko) 플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도
JP7323706B2 (ja) 発毛促進活性を有するペプチド、及びその用途
TW201521758A (zh) 用於使皮膚回春之胜肽及其使用方法
US8952060B2 (en) Composition for preventing hair loss or for stimulating hair growth
US12318429B2 (en) Peptide for preventing or treating hair loss, and use thereof
KR20110131187A (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
AU2024344613A1 (en) Topical compositions and uses of pai-1 inhibitors
KR101623375B1 (ko) 키토산 및 디카르복실산을 포함하는 주사 질환의 치료용 조성물
ES2953088T3 (es) Formulación tópica
JP2025507886A (ja) 二重作用ｐｄｅ５阻害剤／有機硝酸エステルの局所血流の増進のための経皮投薬形態
JP6656890B2 (ja) フィラグリン産生促進剤
HK40055571A (en) Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor
HK40055572A (en) Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
EP4326305A1 (en) Acetyl sh-hexapeptide-5 amide acetate for use in the treatment of hair loss disorders and as a hair care agent
WO2021105695A1 (en) New use of angiotensin ii receptor agonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)